Topic

Articles

AstraZeneca’s acquisition of Amolyt Pharma includes eneboparatide, a Phase III therapeutic peptide for the treatment of hypoparathyroidism.

AstraZeneca to Acquire Amolyt Pharma in Deal Worth Potentially $1.05 Billion 

Feliza Mirasol is the science editor for 

Ricoh aims to create novel disease models for R&D using ERS Genomics’ CRISPR/Cas9 genome editing technology.

Ricoh and ERS Genomics Enter License Agreement for CRISPR/Cas9 Technology

Mapp Biopharmaceutical will use ProBioGen’s GlymaxX technology for the development of an afucosylated antibody against Marburg virus infection

Mapp Biopharmaceutical Teams Up with ProBioGen and to Develop Antibody Against Marburg Virus Disease

Johnson & Johnson’s $2 billion acquisition of Ambrx boosts its pipeline of next-generation ADCs for cancer treatment.

J&J Completes $2 Billion Ambrx Acquisition, Boosts Pipeline for Next-Gen ADCs

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.

AstraZeneca Set to Boost the UK’s Life Sciences Sector with Investment Plans

Under a global license and collaboration agreement, AbbVie and OSE Immunotherapeutics will aim to develop OSE-230, a mAb for treating chronic inflammation.

AbbVie Partners with OSE Immunotherapeutics on Novel mAb for Chronic Inflammation

 in 2014, Adam Goulder has over 30 years' experience within the maintenance engineering and asset management sectors including Pharmaceutical and Medical Devices manufacturing. As Head of Project Management and a Principal Consultant Adam oversees the management and implementation of enterprise asset management solutions to a wide range of organisations across the Pharmaceutical, Medical Devices, Healthcare, Logistics, Facilities Management, Utilities, Oil & Gas, and Transportation sectors. Adam is a Chartered Engineer, holds an MSc in Maintenance Engineering and Asset Management from the University of Manchester and is a member of the International Society of Pharmaceutical Engineers.

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Mike Hennessy Jr. is the President and CEO of 

While Catalent’s acquisition is definitely about making drugs, it’s also very much about making money.

First in Line on Catalent’s Line

Nona Biosciences and Boostimmune will collaborate to develop ADCs against novel targets using Nona’s proprietary platform technology.

Nona Biosciences Partners with Boostimmune on ADC Development

CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen. 

Bio/Pharma Business